The store will not work correctly when cookies are disabled.
4-(7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-2,6-difluorophenol
ID: ALA4855811
PubChem CID: 164618225
Max Phase: Preclinical
Molecular Formula: C12H8F2N4O
Molecular Weight: 262.22
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Oc1c(F)cc(Nc2ncc3cc[nH]c3n2)cc1F
Standard InChI: InChI=1S/C12H8F2N4O/c13-8-3-7(4-9(14)10(8)19)17-12-16-5-6-1-2-15-11(6)18-12/h1-5,19H,(H2,15,16,17,18)
Standard InChI Key: DQQJEXJMRYNRKA-UHFFFAOYSA-N
Molfile:
RDKit 2D
19 21 0 0 0 0 0 0 0 0999 V2000
38.8908 -22.0893 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.8896 -22.9145 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.6026 -23.3264 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.3172 -22.9140 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.3143 -22.0857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.6008 -21.6776 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.5984 -20.8547 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
38.1780 -21.6781 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
38.1766 -23.3255 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
41.0305 -23.3244 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
41.7425 -22.9118 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.4525 -23.3226 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
42.4448 -21.6767 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.7362 -22.0910 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
43.1642 -22.0766 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.1668 -22.9068 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.9573 -23.1608 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
44.4432 -22.4876 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.9530 -21.8175 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
6 7 1 0
1 8 1 0
2 9 1 0
4 10 1 0
10 11 1 0
11 12 2 0
12 16 1 0
15 13 1 0
13 14 2 0
14 11 1 0
15 16 2 0
16 17 1 0
17 18 1 0
18 19 2 0
19 15 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 262.22 | Molecular Weight (Monoisotopic): 262.0666 | AlogP: 2.69 | #Rotatable Bonds: 2 |
Polar Surface Area: 73.83 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 8.28 | CX Basic pKa: 4.84 | CX LogP: 2.62 | CX LogD: 2.56 |
Aromatic Rings: 3 | Heavy Atoms: 19 | QED Weighted: 0.62 | Np Likeness Score: -1.02 |
References
1. Casalvieri KA, Matheson CJ, Warfield BM, Backos DS, Reigan P.. (2021) N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors., 41 [PMID:34034149] [10.1016/j.bmc.2021.116220] |